Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Ongoing Neoadjuvant Clinical Trials in Pancreatic Cancer

February 16th 2017

Neoadjuvant Therapy in Locally Advanced Pancreatic Cancer

February 16th 2017

Advanced Pancreatic Cancer: Quality of Life Considerations

February 16th 2017

Sequencing Decisions in Advanced Pancreatic Cancer

February 16th 2017

Liposomal Irinotecan in Advanced Pancreatic Cancer

February 16th 2017

Frontline Decisions in Metastatic Pancreatic Cancer

February 16th 2017

Metastatic Pancreatic Cancer: Dosing Strategies in the Frontline Setting

February 16th 2017

Current Practice With Molecular Testing in Pancreatic Cancer

February 16th 2017

Multidisciplinary Care in Advanced Pancreatic Cancer

February 16th 2017

The Future of HCC Treatment

February 15th 2017

Evidence With Checkpoint Inhibition in HCC

February 15th 2017

Emerging Multikinase Inhibitors in HCC

February 15th 2017

Emerging c-MET Inhibitors in HCC

February 15th 2017

Current Understanding With Biomarkers in HCC

February 15th 2017

Underlying Cirrhosis in the Second-Line Setting of HCC

February 15th 2017

Incorporating Regorafenib in the HCC Treatment Landscape

February 15th 2017

Improving Survival in HCC

February 15th 2017

Dosing Strategies With Sorafenib in HCC

February 15th 2017

HCC: Timing of Locoregional and Systemic Therapies

February 15th 2017

Locoregional Therapy Options in HCC

February 15th 2017